STOCK TITAN

Armistice Capital (IMNN) discloses 396,718 shares, 9.99% stake

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G disclosing beneficial ownership of 396,718 shares of Imunon, Inc. common stock, representing 9.99% of the class. The filing states Armistice Capital exercises shared voting and dispositive power via an Investment Management Agreement.

Positive

  • None.

Negative

  • None.

Insights

Armistice reports a near-10% position with shared control via an investment manager.

Armistice Capital is disclosed as the investment manager for the Master Fund and is reported to exercise voting and investment power over 396,718 shares of common stock (9.99%). The Master Fund is identified as the direct holder.

The filing clarifies that the Master Fund "specifically disclaims beneficial ownership" due to its inability to vote or dispose of the shares under the Investment Management Agreement; cash-flow treatment and any planned disposition activity are not included in the excerpt.

Shares beneficially owned 396,718 shares Amount beneficially owned reported in Item 4(a)
Percent of class 9.99% Percent of class reported in Item 4(b)
Shared voting power 396,718 shares Shared power to vote reported in Item 4(c)(ii)
CUSIP 15117N701 CUSIP for Imunon common stock
Signature date May 15, 2026 Date of joint filing/signature
Investment Management Agreement regulatory
"Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd."
An investment management agreement is a written contract that hires a professional to make buying, selling and strategy decisions for an investment account or fund, and sets out their duties, fees, risk limits, performance measures and reporting requirements. It matters to investors because the agreement determines who controls the money, how much the service costs, what risks are allowed, and how success or failure is measured—think of it as the service contract that defines expectations and remedies for a hired portfolio manager.
Beneficial ownership regulatory
"Armistice Capital exercises voting and investment power over the securities of the Issuer"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Schedule 13G/A regulatory
"Amendment No. 1 ... SCHEDULE 13G/A disclosure of beneficial ownership"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.





15117N701

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:05/15/2026
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:05/15/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: May 15, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

What stake does Armistice Capital report in IMNN?

Armistice Capital reports beneficial ownership of 396,718 shares, equal to 9.99% of Imunon, Inc.'s common stock. The shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital acts as investment manager.

Who has voting and dispositive power over the reported IMNN shares?

The filing states Armistice Capital exercises both voting and investment power over the shares held by the Master Fund, with shared voting power and shared dispositive power of 396,718 shares as reported.

Does the Master Fund claim beneficial ownership in the filing?

The Master Fund is named as the direct holder, but the filing expressly states the Master Fund "specifically disclaims beneficial ownership" because it lacks the ability to vote or dispose of the securities under its Investment Management Agreement.

When was the Schedule 13G/A amendment signed for IMNN?

The joint amendment is dated and signed May 15, 2026 by Steven Boyd as Managing Member of Armistice Capital, LLC, and filed as an amendment to the Schedule 13G disclosure regarding beneficial ownership.